April 2026 Research Update

This month included two treatment-focused reports with different levels of evidence, and the overall picture was mixed. A phase 2 trial of amlenetug (an antibody designed to target clumped alpha-synuclein) did not meet its main goal for slowing MSA progression. A separate registry report suggested that continuous subcutaneous apomorphine infusion may help some people with MSA with motor fluctuations over 6 months, but it did not include a comparison group, so it cannot show how much change was due to the treatment versus the natural ups and downs of symptoms. [1] [2]

In AMULET, people receiving amlenetug were compared with placebo, and the trial did not reach the prespecified bar for evidence that progression slowed on the UMSARS total score over 72 weeks. The researchers reported an 89.4% probability of a true slowing in their Bayesian analysis, which was below their required 97.5% threshold, meaning the trial result was not considered a success by its own rules. Safety was reported as generally comparable between groups, with frequent side effects reported in both groups. [1]

In the French registry, 50 people with MSA (mostly MSA-P) received continuous subcutaneous apomorphine infusion for motor fluctuations, and most were rated as at least minimally improved at 6 months on a global impression scale. Improvements were mainly attributed to reduced motor fluctuations, and tolerability was rated good to excellent for most, while some people experienced sleepiness or low blood pressure when standing. Because this was a retrospective registry without a control group, it provides a real-world signal of possible benefit for selected symptoms, but it cannot prove the treatment caused the improvements. [2]

For patients and caregivers, the clearest new information this month is that one disease-modifying style approach aimed at alpha-synuclein (amlenetug) did not meet its main trial endpoint, even though the study still observed a probability signal that researchers may explore further. The apomorphine infusion report is more about symptom management in routine care, and it adds practical information that some people with MSA and motor fluctuations were able to stay on the infusion for 6 months with reported improvement, while side effects like sleepiness and orthostatic hypotension were also seen. Together, these studies mainly add clarity about what is and is not yet proven, rather than establishing a new standard approach. [1] [2]

Several studies this month worked on better ways to distinguish MSA from similar conditions, and the pattern is that no single test solves the problem, but different tools may contribute different pieces. Imaging approaches (MRI and a nuclear heart scan) and fluid or tissue biomarkers (CSF metabolites and skin biopsy staining) all reported signals that can separate groups in research settings. At the same time, a large real-world review highlighted that commonly used diagnostic imaging can be hard to interpret because everyday medications and other health conditions can interfere with results. [3] [4] [5] [6] [7]

MRI-based work suggested that combining several brain measures may separate Parkinson's disease from MSA very well in that research dataset, with different patterns of extra brain water in each condition and evidence of worsening over time in the regions most affected. This kind of panel approach matters because MSA diagnosis often depends on patterns rather than a single definitive marker, and this study suggests that putting measures together may improve separation compared with relying on one scan feature alone. The report does not establish how well this would perform in everyday clinics outside the study setting. [3]

Across many prior studies, QSM MRI (an MRI method that estimates iron-related changes) showed disorder-specific patterns: putamen changes were more pronounced in MSA, while other regions were more prominent in Parkinson's disease or PSP. The meta-analysis reported moderate diagnostic performance, and it also emphasized that differences in scanners and MRI methods make results vary across studies, which is one reason this tool is not yet a simple yes-or-no test. This helps explain why imaging can be informative but still inconsistent from place to place. [6]

Body-based biomarkers were also explored, including a skin biopsy method that measured phosphorylated alpha-synuclein inside small nerves and a CSF metabolite panel that separated MSA and PSP from controls with high accuracy in that dataset. The skin biopsy study found higher signal in synuclein disorders (including MSA) than in PSP, but it did not distinguish MSA from Parkinson's disease in that small sample. The CSF metabolomics study reported that overall metabolite patterns were not cleanly separated, yet selected metabolite combinations performed better, including only moderate separation between MSA and PSP. [5] [4]

Swallowing and breathing coordination testing added another possible differentiator: in this retrospective analysis, people with MSA showed broader swallowing problems and more disrupted timing between swallowing and breathing than people with Parkinson's disease, especially in MSA-C. A specific index related to breathing after swallowing helped distinguish MSA from Parkinson's disease in their dataset, suggesting that detailed measurement of swallowing-breathing patterns could capture differences that match everyday symptoms such as choking or coughing with liquids. The study does not state how this would compare to standard swallowing studies in routine care. [8]

A large retrospective review of cardiac MIBG scans highlighted a practical limitation: more than half of patients had at least one factor that could affect tracer uptake, most often medication interactions or other medical conditions. This matters because a scan can look abnormal for reasons unrelated to the brain disease, which can muddy interpretation when trying to separate Parkinson's disease from atypical parkinsonism such as MSA. The study focuses on how often these limiting factors show up in real records, not on improving scan accuracy. [7]

Finally, a very large autopsy-based study across parkinsonian disorders reported that clinical misdiagnosis still occurs at meaningful rates, and it documented how mixed pathologies and genetic factors complicate classification. While it was not focused only on MSA, it reinforces why multiple different diagnostic signals are being pursued, since symptoms during life do not always match what is found in the brain at autopsy. It also supports the idea that combining clinical, genetic, and pathology information may be needed to improve certainty in the long run. [9]

A separate guideline document described how integrated PET/MRI can be used and interpreted for Parkinson's disease and for differentiating Parkinson's disease from atypical parkinsonian syndromes. This does not provide new study results, but it shows that multimodal imaging approaches are being formalized into workflows where the technology is available. Its recommendations are framed within Chinese clinical practice and access to equipment. [10]

For patients, this set of studies adds to a realistic picture: diagnosis research is moving toward using patterns across multiple measures, rather than expecting one definitive test. Some research tools showed strong separation between conditions in specific datasets (for example, combined MRI measures), while other approaches looked promising but did not separate MSA from Parkinson's disease in small samples (for example, the skin biopsy alpha-synuclein burden). A separate real-world scan review is a reminder that even established tests can be affected by common medications and health conditions, which can make results harder to interpret. These findings may matter more over time as studies are repeated and standardized, rather than changing diagnosis immediately for most people. [3] [5] [7]

This month also added several pieces about what might be happening in MSA at the tissue and body level, and the overall direction points to glial (support cell) involvement alongside broader cell-stress signals. Studies of human brain tissue and models reported altered astrocyte and microglia behavior and damage signals related to oligodendrocytes, the cells that help insulate nerve fibers. Other human studies reported blood markers (NfL and BDNF) that differed across groups, and imaging work described subtype-related brain metabolism and dopamine-system differences within MSA. [11] [12] [13] [14] [15] [16]

At a cell level, one postmortem study comparing MSA and Parkinson's disease reported that MSA tissue showed fewer signs of activated microglia but more reactive astrocytes, along with impaired oligodendrocyte-related signaling. In supporting lab experiments, microglia exposed to patient cerebrospinal fluid showed reduced ability to engulf material, with the strongest reduction reported for MSA, which fits the idea of an immune response that is present but not functioning normally. This helps sharpen the question of whether immune changes in MSA are more about immune exhaustion or tolerance than classic inflammation. [11]

A separate translational study pointed to astrocytic FABP5 as a possible driver of oligodendrocyte injury through inflammatory and oxidative damage pathways, including TNF-alpha signaling and lipid peroxidation. In their models, reducing FABP5 in astrocytes rescued oligodendrocytes from injury, which is an early step toward identifying drug targets, not a tested therapy. Together with the microglia study, this supports the idea that neighboring support cells can influence the cells most directly injured in MSA. [12] [11]

Broader brain-tissue gene expression work across many parkinsonian disorders found a common pattern of reduced neuronal signals with stronger glial signatures, plus downregulation of pathways tied to energy production and protein handling. In that analysis, MSA sat between Lewy body diseases and tau disorders in overall similarity, which may help explain why symptoms and test findings can sometimes overlap across these diagnostic categories. This kind of map does not diagnose an individual person, but it organizes which biological processes look shared versus different across diseases. [13]

Within MSA specifically, a large PET imaging study reported that MSA-P and MSA-C have distinct brain metabolism patterns, and MSA-P showed greater loss of dopamine transporter signal than MSA-C and controls. The study also reported that relationships between these imaging patterns and disease duration differed by age and sex in some analyses, suggesting that progression markers might not look the same in everyone. This helps explain why tracking MSA can be challenging and why subtype-aware measures are being developed. [14]

Blood biomarker studies added two different signals. Plasma neurofilament light chain (NfL), a marker of nerve fiber injury, was elevated in isolated REM sleep behavior disorder and was especially high in those with neurogenic orthostatic hypotension, with all observed MSA converters in that cohort having orthostatic hypotension at baseline. Separately, serum BDNF was reported to be higher in MSA and dementia with Lewy bodies than in healthy controls, which the authors discussed as possibly compensatory or dysregulated, but the report did not establish how well it tracks MSA severity or change over time. [15] [16]

Genetic and epigenetic work at the MOBP locus suggested that strong shared risk mechanisms were clearer for ALS and PSP than for MSA, with a specific methylation signal seen in PSP but not detected in MSA or Parkinson's disease. This matters for MSA because it argues against assuming that a risk mechanism in one neurodegenerative disease automatically applies to another, even when symptoms can overlap. The study still leaves open whether MOBP-related changes matter in MSA through different pathways not captured by the specific signal they tested. [17]

A very large population study in the UK Biobank linked liver-related markers to future risk of several neurodegenerative diseases, but it reported only a single liver-related factor for MSA. This kind of work does not show cause-and-effect for any one person, yet it broadens the research view toward whole-body health signals that might connect to brain outcomes. For MSA specifically, the finding is too limited in this summary to conclude which liver marker matters or how useful it could be. [18]

One preclinical imaging development study compared experimental PET tracers intended to bind alpha-synuclein in Parkinson's disease and MSA. The authors reported problems such as low binding specificity, off-target binding to amyloid plaques for one tracer, and rapid metabolism in non-human primates for another, leading them to conclude that one tracer was not a good candidate for further translation. This is laboratory and animal research, but it helps explain why an accurate alpha-synuclein brain scan remains difficult to develop. [19]

For patients and caregivers, these biology studies mainly add understanding rather than offering a new test or treatment now. The work strengthens the idea that MSA is not only about neurons, but also about support cells in the brain (astrocytes, microglia, and oligodendrocytes) and how they respond to stress and inflammation, which could shape future drug targets. Blood and imaging markers (like NfL, BDNF, and PET patterns) may become useful for tracking disease or identifying subgroups, but the summaries here do not show that any one marker is ready to guide individual decisions. What remains uncertain is which of these signals are drivers of the disease versus byproducts, and which can be measured reliably across different clinics and stages of MSA. [11] [12] [14] [15] [16]